Leading ASX listed Cancer drug specialist Pharmaust, are in discussions with a UK-based clinical oncologist to evaluate their anti-cancer drug known as Monepantel in patients with oesophageal cancer. The trials, which will analyse the effect of Monepantel on patient’s tumours are designed to provide short term feedback on the efficacy of the drug.
![](https://static.businessnews.com.au/sites/all/themes/bn2020/images/squares.gif)